Navigation Links
Effective Vaccine for Leishmaniasis in the Pipeline

Leishmaniasis is a parasitic disease that kills about 60,000 people annually. It spreads by the bite of infected female sand flies. // Visceral leishmaniasis infects about 500,000 people annually mainly in India, Bangladesh, Nepal, Sudan and Brazil. The most common drugs to treat leishmaniasis have serious side effects and are expensive. Symptoms of visceral leishmaniasis include fever, weight loss, and abnormalities of the liver and spleen. As there is no effective vaccine for the visceral, or internal, form of leishmaniasis till date there is an increase in the death rate due to the disease. Peter H. Seeberger, Ph.D., of the Laboratory for Organic Chemistry at the Swiss Federal Institute of Technology (ETH) in Zurich developed a fundamentally new vaccine for the disease. The research team consisted of scientists from the Swiss Tropical Institute in Basel and Pevion Inc., a biotech company focusing on virosomal delivery systems.

The results of the research findings were reported in ACS Chemical Biology, one of 34 peer-reviewed journals published by the American Chemical Society, the world’s largest scientific society. Several leishmaniasis candidate vaccines are in various stages of development. The vaccine is a new genre of carbohydrate-based vaccines. Carbohydrates are chemical compounds that include sugar which are linked together. The vaccine is not only useful in humans but can be used to protect pets (dogs) against leishmaniasis. Carbohydrate vaccines are used in everyday medicine, including vaccines to immunize against meningitis and other bacterial infections, mainly in small children in the United States. Those vaccines use carbohydrates isolated from the actual bacteria responsible for the diseases.

The carbohydrates act as antigens, which stimulate the immune system to produce antibodies. But now synthetic carbohydrates are used as antigens in order to control the purity and composition and avoid possible contamination. But one major drawback with carbohydrate vaccines is the difficulty in getting them to produce a strong immune response. Vaccine manufacturers achieve this by adding a booster substance called adjuvant. Seeberger’s vaccine against leishmaniasis combines the delivery vehicle, immune-stimulating antigen and adjuvant into one package.

The delivery vehicle is an influenza virosome that is an empty envelope of the influenza virus. They contain none of the infectious genetic material of the flu viruses. The virosome also acts as an adjuvant, boosting the immune response of the vaccine. The antigen is a synthetic carbohydrate similar to substances on the surface of the leishmaniasis bacteria. Seeberger’s group is planning to test the vaccine on animals. WHO assigned a high priority to development of a leishmaniasis vaccine because of the huge human toll and the lack of any effective treatment.

'"/>




Related medicine news :

1. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
2. Inhaled Steroids Safe & Effective for Children with Asthma
3. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
4. Fluoride Found Effective in Osteoporosis
5. Aspirin and Warfarin Are Equally Effective for Stroke Prevention
6. Implantable Contact Lens Found Safe and Effective
7. Effective And Economical Agent For Anthrax
8. Stem Cell Transplants May Be Effective For MS Patients
9. Effective therapy for Huntingtons disease
10. Chemotherapy Effective for Bladder Cancer
11. Drug Effective for Vascular Dementia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/4/2016)... Durham, NC (PRWEB) , ... May 04, 2016 ... ... healthcare professionals in medical coding, billing and compliance. In upcoming months, AudioEducator has ... on various specialties. Every conference is designed to give complete compliance know-how and ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... Patient 2016, a powerful cellular therapy software application that helps blood and ... to patients. , Since Transtem’s initial launch, Mediware has continued to enhance core ...
(Date:5/4/2016)... ... ... Fertility Centers of New England announced today the opening of their newest location ... access to care for patients seeking fertility treatment in Maine. “We are delighted to ... Portland,” said Fertility Centers of New England President and CEO, Joseph A. Hill, M.D. ...
(Date:5/3/2016)... , ... May 04, 2016 , ... ... 40 national and global construction firms representing the Construction Industry Safety Initiative (CISI) ... forces with one purpose: to inspire everyone in the industry to be leaders ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... Business Journal, patients report dissatisfaction with numerous issues related to medical care in ... with billing, and poor bedside manner from hospital staff. Commenting on this article, ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... May 3, 2016 ... dass sie einen entscheidenden Meilenstein durch diese ... Aufruf zum Handeln, um Patientenresultate  bei Verdauungs- ... zu Fortschritten im Verständnis der Hepatischen Enzephalopathie ... Bewusstsein für Hepatische Enzephalopathie in der Öffentlichkeit ...
(Date:5/2/2016)... May 2, 2016  While nearly three-quarters of Americans ... have on their health, only about half report taking ... the results of a new survey announced today by ... start of National Osteoporosis Month, Hologic is raising awareness ... nearly 56 million Americans. Osteoporosis is a ...
(Date:4/29/2016)... , April 29, 2016 ... Review, H1 2016" market research report that provides ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
Breaking Medicine Technology: